Hypoxia-mediated cancer stem cell resistance and targeted therapy - 27/10/20
, Xuemei Lv a, b , Yuanyuan Yan a, b , Yanyun Zhao a, b , Rong Ma a, b , Miao He a, b, ⁎ , Minjie Wei a, b, ⁎ Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 8 |
| Iconografia | 3 |
| Video | 0 |
| Altro | 0 |
Graphical abstract |
Highlights |
• | Cancer stem cells (CSCs) are regarded as one of the important targets that mediate tumor resistance. |
• | Tumor hypoxic microenvironment plays an important role in regulating resistance of CSCs to chemotherapy and radiotherapy. |
• | Hypoxia maintains the stemness of CSCs through regulation of self-renewal signaling pathways, microRNAs, drug transporters and EMT. |
• | HIFs have emerged as therapeutic targets in cancer therapy. |
Abstract |
Drug resistance is a major obstacle in the treatment of tumors, which easily lead to relapse or poor prognosis. Cancer stem cells (CSCs) are regarded as one of the important targets that mediate tumor resistance. Increasing evidence shows that the tumor hypoxia microenvironment is closely related to the resistance of CSCs to chemotherapy and radiotherapy. In this review, we intend to review the articles that have described how the hypoxic microenvironment affects CSC stemness and mediates tumor resistance and provide new directions and methods in the clinical treatment of tumors. Here, we also discuss the feasibility and development prospects of using hypoxia-inducible factors (HIFs) that regulate the hypoxic microenvironment of tumors as targeted agents to treat tumors, as well as to reduce or even reverse the resistance of tumors to chemotherapy and radiotherapy.
Il testo completo di questo articolo è disponibile in PDF.Abbreviations : CSC, HIF, HRE, ADT, PTX, bHLH, PAS, ODD, TAD, N-TAD, C-TAD, pVHL, PDAC, RP2D
Keywords : Cancer stem cells (CSCs), Hypoxia inducible factors (HIFs), Tumor resistance, HIF inhibitors
Mappa
Vol 130
Articolo 110623- Ottobre 2020 Ritorno al numero
Articolo precedente
- Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers
- Li Wang, Jialin Qu, Na Zhou, Helei Hou, Man Jiang, Xiaochun Zhang
- Immune boosting functional foods and their mechanisms: A critical evaluation of probiotics and prebiotics
- Tolulope Joshua Ashaolu
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?